- Home
- INTG vs KLRS Comparison
INTG vs KLRS Comparison
Compare INTG & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTG
- KLRS
- Stock Information
- Founded
- INTG 1965
- KLRS 2019
- Country
- INTG United States
- KLRS United States
- Employees
- INTG N/A
- KLRS N/A
- Industry
- INTG Building operators
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INTG Real Estate
- KLRS Health Care
- Exchange
- INTG Nasdaq
- KLRS Nasdaq
- Market Cap
- INTG 38.9M
- KLRS 46.0M
- IPO Year
- INTG N/A
- KLRS N/A
- Fundamental
- Price
- INTG $36.30
- KLRS $4.78
- Analyst Decision
- INTG
- KLRS Strong Buy
- Analyst Count
- INTG 0
- KLRS 3
- Target Price
- INTG N/A
- KLRS $21.50
- AVG Volume (30 Days)
- INTG 17.7K
- KLRS 107.9K
- Earning Date
- INTG 11-14-2025
- KLRS 11-13-2025
- Dividend Yield
- INTG N/A
- KLRS N/A
- EPS Growth
- INTG N/A
- KLRS N/A
- EPS
- INTG N/A
- KLRS N/A
- Revenue
- INTG $64,378,000.00
- KLRS N/A
- Revenue This Year
- INTG N/A
- KLRS N/A
- Revenue Next Year
- INTG N/A
- KLRS N/A
- P/E Ratio
- INTG N/A
- KLRS N/A
- Revenue Growth
- INTG 10.73
- KLRS N/A
- 52 Week Low
- INTG $9.57
- KLRS $2.14
- 52 Week High
- INTG $42.50
- KLRS $23.69
- Technical
- Relative Strength Index (RSI)
- INTG 62.61
- KLRS 47.17
- Support Level
- INTG $33.84
- KLRS $4.67
- Resistance Level
- INTG $38.22
- KLRS $5.10
- Average True Range (ATR)
- INTG 4.64
- KLRS 0.41
- MACD
- INTG -0.60
- KLRS -0.03
- Stochastic Oscillator
- INTG 59.71
- KLRS 39.41
About INTG Intergroup Corporation (The)
The Intergroup Corp is an us-based company operating in the real estate sector. It is formed to buy, develop, operate, rehabilitate and dispose of real property of various types and descriptions, and to engage in other related business and investment activities. The company operates through three segments namely Hotel Operations, Real Estate Operations, and Investment Transactions. The Hotel Operations segment which generates the majority of the revenue covers the operation of the Hilton hotel and garage. The Real Estate Operations segment consists of the operation of multifamily rental properties whereas the Investment Transactions segment includes an investment of cash in marketable securities and other investments.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.